Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 4/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17895701 | 0.84 | TUBB4A (0.36) | DYRK1APIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL17895666 | 0.78 | APP (0.38) | PIK3CAPIK3CGNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17895688 | 0.78 | PIK3CG (0.38) | DYRK1APIK3CAPIK3CGNPC1RAB9A | |
| SCHEMBL17895618 | 0.73 | ALOX5 (0.39) | PIK3CAPIK3CGALOX5PDE5APDE4D | |
| SCHEMBL17895681 | 0.68 | NPC1 (0.38) | DYRK1ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17895651 | 0.66 | RAB9A (0.36) | DYRK1ANPC1RAB9APPARA | |
| SCHEMBL17895625 | 0.64 | CASR (0.44) | NPC1RAB9AALOX5 | |
| SCHEMBL19251089 | 0.61 | CHRNB2 (0.39) | DYRK1ACLK4 | |
| SCHEMBL17895667 | 0.60 | RAB9A (0.41) | DYRK1ANPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL17895608 | 0.60 | PIK3CG (0.39) | DYRK1APIK3CAPIK3CGNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434234-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2022-09-06 | — | — | US | claimed |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. | 2021-10-21 | — | — | US | claimed |
| US-10851095-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2020-12-01 | — | — | US | claimed |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2019-08-22 | — | — | US | claimed |
| US-10287282-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2019-05-14 | — | — | US | claimed |
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2018-01-04 | — | — | US | claimed |
| EP-3240778-A1 | METHODS AND AGENTS FOR TREATING DISEASE | Angion Biomedica Corp. (US) | 2017-11-08 | — | — | EP | claimed |
| WO-2016109492-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP (US) | 2016-07-07 | — | — | WO | claimed |
| US-11434234-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. | 2021-10-21 | — | — | US | disclosed |
| CN-107531631-B | Methods and agents for treating diseases | 安吉昂生物医药公司 | 2021-09-03 | — | — | CN | disclosed |
| US-10851095-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2019-08-22 | — | — | US | disclosed |
| US-10287282-B2 | Methods and agents for treating disease | ANGION BIOMEDICA CORP. (US) | 2019-05-14 | — | — | US | disclosed |
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| EP-3240778-A1 | METHODS AND AGENTS FOR TREATING DISEASE | Angion Biomedica Corp. (US) | 2017-11-08 | — | — | EP | disclosed |
| WO-2016109492-A1 | METHODS AND AGENTS FOR TREATING DISEASE | ANGION BIOMEDICA CORP (US) | 2016-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002324-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | DYRK1A 4772/4885PIK3CA 1575/4885PIK3CG 2519/4885 |
| US-11434234-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | DYRK1A 4378/4885PIK3CA 1985/4885PIK3CG 2846/4885 |
| US-10851095-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | DYRK1A 4378/4885PIK3CA 1985/4885PIK3CG 2846/4885 |
| US-10287282-B2 | Methods and agents for treating disease | REN, NR3C2, CYP11B2 | DYRK1A 4772/4885PIK3CA 1575/4885PIK3CG 2519/4885 |
| US-20190256507-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | DYRK1A 4378/4885PIK3CA 1985/4885PIK3CG 2846/4885 |
| US-20210323955-A1 | METHODS AND AGENTS FOR TREATING DISEASE | REN, NR3C2, CYP11B2 | DYRK1A 4378/4885PIK3CA 1985/4885PIK3CG 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.